The influence of driver mutations on leukaemic transformation was analysed in 1747 patients with polycythaemia vera or essential thrombocythaemia. With a median follow-up of 7Á2 years, 349 patients died and 62 progressed to acute leukaemia or myelodysplastic syndrome. Taking death as a competing risk, CALR genotype was associated with a lower risk of transformation [subdistribution hazard ratio (SHR): 0Á13, 95% confidence interval (CI): 0Á2-0Á9, P = 0Á039], whereas JAK2 V617F showed borderline significance for higher risk (SHR: 2Á05, 95% CI: 0Á9-4Á6, P = 0Á09). Myelofibrotic transformation increased leukaemic risk, except in CALRmutated patients. Next generation sequencing of 51 genes at the time of transformation showed additional mutations (median number: 3; range: 1-5) in 25 out of 29 (86%) assessable cases. Mutations (median: 1; range: 1-3) were detected in 67% of paired samples from the chronic phase. Leukaemia appeared in a JAK2 V617F negative clone in 17 (58%) cases, eleven of them being previously JAK2 V617F-positive. JAK2 V617F-mutated leukaemia was significantly associated with complex karyotype and acquisition of TP53 mutations, whereas EZH2 and RUNX1 mutations were more frequent in JAK2 V617F-negative leukaemia. Survival was longer in JAK2 V617F-unmutated leukaemia (343 days vs. 95 days, P = 0Á003). In conclusion, CALR genotype is associated with a lower risk of leukaemic transformation. Leukaemia arising in a JAK2 V617F-negative clone is TP53 independent and shows better survival.
Patients with myeloproliferative neoplasms (MPN) who develop acute myeloid leukaemia (AML) have poor prognosis, with a median survival of 3-6 months (Tam et al, 2008; Kennedy et al, 2013) . In polycythaemia vera (PV) or essential thrombocythaemia (ET), the frequency of AML transformation ranges from 2% to 5% of patients (Kiladjian et al, 2011; Tefferi et al, 2013 Tefferi et al, , 2014a . Currently, the identification of risk factors predicting for leukaemic transformation, as well as the prognostic stratification and treatment strategy following disease transformation, constitute unmet clinical needs.
Advanced age, leucocytosis, cytogenetic abnormalities and exposure to leukaemogenic agents are well-established risk factors for transformation into AML in patients with PV and ET (Finazzi et al, 2005; Gangat et al, 2007a,b; Passamonti et al, 2008; Kiladjian et al, 2011; Hern andez-Boluda et al, 2012; Tefferi et al, 2013) . Although, the prognostic value of genotype [JAK2, CALR, MPL or triple negative (TN)] has been widely studied in patients with myelofibrosis (MF) (Guglielmelli et al, 2011; Vannucchi et al, 2013; Rumi et al, 2014a; Tefferi et al, 2014a,b,c) , few studies have addressed this subject in patients with PV or ET (Lundberg et al, 2014; Rotunno et al, 2014; Rumi et al, 2014b; Palandri et al, 2015) .
Notably, JAK2 V617F-mutated MPNs can develop AML in the JAK2 V617F-positive or in the JAK2 V617F-negative clone, suggesting the existence of different pathways of disease transformation (Campbell et al, 2006) . However, the spectrum of molecular abnormalities and the clinical outcome according to the JAK2 V617F mutational status of the leukaemic clone are not well characterised.
The objective of the present study was to analyse the influence of the genotype on the risk of AML/myelodysplastic syndrome (MDS) transformation in patients with PV and ET. In addition, we aimed to determine if the JAK2 V617F mutational status of the leukaemic clone is related with a different transformation pathway and outcome.
Patients and methods

Clinical data
The medical charts of patients consecutively diagnosed with PV and ET in five institutions in Spain from 1973 to 2015 were reviewed. In every case, the diagnosis of PV and ET was reassessed using the of the World Health Organization criteria (Tefferi et al, 2007) . The indication of cytoreductive therapy was decided according to the criterion of the attending haematologist on the basis of the clinical guidelines and prevailing recommendations at that time. Informed consent for the scientific use of the patients' clinicohaematological data and biological samples was obtained in accordance with the requirements of the local ethics committees.
Molecular analysis
Targeted next-generation sequencing (NGS) was performed on DNA extracted from mononuclear cells at the time of acute transformation of the disease. Targeted amplicon libraries were constructed using the Human Myeloid Neoplasms GeneRead DNAseq Targeted Panel V2 (Qiagen, Hilden, Germany), a commercially available panel covering the full exonic regions of 50 commonly mutated genes in myeloid malignancies and were sequenced using either MiSeq or NextSeq (Illumina, San Diego, CA, USA). Genes tested in the panel are as follows :  ABL1, ASXL1, ATRX, BCOR, BCORL1, CBL, CBLB, DAXX,  DNMT3A, EED, ETV6, EZH2, FLT3, GATA1, GNAS, IDH1,  IDH2, IKZF1, JAK1, JAK2, JAK3, KAT6A, KIT, KRAS, KMT2A  (MLL), MPL, NF1, NPM1, NRAS, PHF6, PRPF40B, PTPN11,  RAD21, RB1, RUNX1, SETBP1, SF1, SF3A1, SF3B1, SH2B3,  SMC1A, SMC3, STAG2, SUZ12, TET2, TP53, U2AF1, U2AF2,  WT1, ZRSR2 . Secondary analysis was performed using MiSeq Reporter Software 2.4 (Illumina) and variants were annotated using Illumina VariantStudio v2.2. Nonsynonymous coding and splice site variants were considered when variant allele frequency (VAF) was greater than 2% unless previously reported as benign or germline polymorphisms.
Relevant genetic regions not properly covered by the gene panel used were sequenced on a 454 GS Junior (Roche, Basel, Switzerland) including SRSF2 (exon 1) and ASXL1 (exon 12). Additionally, all patients were screened for CALR, NPM1 and FLT3 mutations using fragment analysis on an ABI3500DX (Applied Biosystems, Foster City, CA, USA). Those variants not previously described in databases or literature, were sought in constitutive DNA from paired samples when the allele frequency suggested potential germline origin using Sanger sequencing in an ABI3500DX. Mutations with a VAF <10% were confirmed by sequencing on a 454 GS Junior or by allele-specific oligonucleotide polymerase chain reaction (PCR) on a 7500 Fast Real-Time PCR System (Applied Biosystems). All confirmed somatic mutations were then sought and quantified in the first available paired sample from the moment of diagnosis or chronic phase of the disease using a 454 GS Junior. See Supplemental Methods for details.
Statistics
Overall survival curves were drawn by the Kaplan and Meier method. The cumulative incidence of AML/MDS transformation was calculated by taking death as a competing risk. Multivariate analyses of factors predicting the haematological transformation were done within the framework of competing risks by the method of Fine and Gray (1999) . Variables evaluated for their potential prognostic significance were age (>65 years vs. ≤65 years), sex, haematological values at diagnosis, presence of cytogenetic abnormalities, cytoreductive therapy and genotype. Regarding cytoreductive therapy, each drug was explored individually and also the exposure to any leukaemogenic agent (radioactive phosphorus, busulfan, melfalan, pipobroman). All the statistical analyses were performed with STATA, version 11 (www.stata.com). Curves of the cumulative incidence of AML/MDS and the competing risk of dying without AML/MDS were drawn by the "stcompet" STATA module developed by Coviello and Boggess (2004) .
Results
Characteristics of the patients
A total of 1747 patients diagnosed with PV (n = 896) or ET (n = 851) were included in the study. The main clinical and laboratory characteristics of the patients at MPN diagnosis are shown in Table I . MPL-mutated patients were significantly older at ET diagnosis (median 73 years in comparison with 65 years, 53 years and 57 years for JAK2 V617F, CALR and TN genotypes, respectively P < 0Á001). During the observation period, 215 (12%) patients received at least one leukaemogenic agent, including radioactive phosphorus (n = 119), busulfan (n = 89), melfalan (n = 15), or pipobroman (n = 1). In 132 (8%) patients, sequential treatment with hydroxycarbamide plus a leukaemogenic agent was administered. There were no significant differences in the proportion of patients with PV and ET who received any leukemogenic agent or sequential therapy. However, patients with PV more frequently received busulfan, whereas ET patients were more commonly treated with radioactive phosphorus. Sixty patients received interferon (see Supporting Information for details). Follow-up was longer in ET patients due to the inclusion of a higher proportion of ET patients diagnosed before year 2000.
Survival, time to AML/MDS transformation and risk factors
With a median follow-up of 7Á2 years (range: 0Á1-42), 349 patients died, resulting in a projected median survival for the overall series of 22 years (95% CI: 19Á7-24Á5). In ET, median survival was not reached in CALR-mutated patients, in comparison with 21, 18 and 11 years for those with JAK2, TN and MPL genotypes, respectively (P < 0Á0001, Figure S1 ).
Overall, 54 patients developed AML and eight patients MDS. At 10 years, the cumulative incidence of progression to AML/MDS was 3Á3% (95% CI: 1Á9-4Á4). The incidence rate of AML/MDS was slightly higher in ET than in PV but the difference was not statistically significant. There were no statistical significant differences in AML/MDS progression according to year of diagnosis (see Supporting Information). Progression to AML/MDS in PV and ET is shown in Figure S2 . Twenty-four patients with ET, all JAK2 V617-positive, evolved into PV, and one of them subsequently developed AML. A total of 144 patients progressed to MF (67 post-ET and 77 post-PV), with 14 of them evolving into AML/MDS afterwards.
After a median time of 8Á8 years (range: 1Á2-28Á9) from PV diagnosis, 26 patients progressed to AML/MDS (24 AML, 2 MDS), with a cumulative incidence of 2Á5% at 10 years. On multivariate analysis, the only factors independently associated with a higher risk of myeloid transformation were leucocytosis >10 9 10 9 /l at PV diagnosis, exposure to leukaemogenic agents and abnormal cytogenetics (Tables II  and SI) . In ET, a total of 36 patients developed AML/MDS (30 AML, 6 MDS) after a median follow-up of 9Á5 years (range: 2Á8-27Á6), resulting in a cumulative incidence of 3Á8% at 10 years. In multivariate analysis, factors associated with a higher incidence of AML/MDS were male sex, exposure to leukaemogenic agents, prior evolution to MF and genotype, with the latter computed as one variable with four categories (Table III) . Age at diagnosis was not associated with a higher risk of AML/MDS transformation and, when included in the multivariate model, it did not affect the prognostic value of genotype (data not shown). The cumulative incidence of AML/MDS according to genotype is shown in Fig 1. When each genotype was singled out and compared to the remaining, CALR mutation showed the lowest risk of acute transformation, with only one patient developing AML after 25 years of follow-up (subdistribution hazard ratio [SHR]: 0Á13, 95% CI: 0Á2-0Á9, P = 0Á039). JAK2 V617F mutation was associated with a borderline significance (SHR: 2Á05, 95% CI: 0Á9-4Á6, P = 0Á09), while MPL and TN lacked any prognostic significance. With regard to post-ET MF, 11 out of 67 (16%) patients with this evolution pattern progressed to AML/MDS ( Figure S3 ). According to the genotype of post-ET MF, the proportion of patients progressing to AML/ MDS for the JAK2 V617F, CALR, MPL and TN genotypes was 5 out of 28 (18%), 1 out of 20 (5%), 1 out of 3 (33%) and 3 out of 4 (75%), respectively.
Molecular studies at time of transformation and in paired samples from the chronic phase
Twenty-nine patients were studied by targeted NGS at the time of transformation (27 AML, 2 MDS). Somatic mutations other than JAK2, CALR or MPL were found in 25 out of 29 patients (86%) (Fig 2 and Table SII ). Median number of mutations was 3 (range: 1-5). Five (17%) patients had one, 7 (24%) two, 9 (31%) three and 4 (14%) four or more additional mutations. The frequencies of mutated genes were: TP53 38%, TET2 28%, RUNX1 17%, DNMT3A 17%, IDH1/2 17%, ASXL1 17%, EZH2 14%, SRSF2 10%, SETBP1 10%, and <5% for CBL, PTPN11, SH2B3, SF3B1, NOTCH1, ETV6, NF1, ZRSR2, NRAS, KRAS, NPM1 and FLT3. The mutational profile of each patient at the time of transformation is shown in Fig 2. The majority of mutated genes were equally distributed among patients with post-PV and post-ET AML, with the exception of EZH2, which appeared to be more frequently mutated in patients with TN ET.
Paired samples from the chronic phase were available in 20 out of 29 transformed cases. These samples were collected at PV or ET diagnosis in 11 cases (55%) or during follow-up in the remaining nine patients after a median time of 9 years (range: 5-17). The VAF among pre-and post-transformation samples is shown in Fig 3. As can be seen, all mutations, except for JAK2 V617F, were stable or increased at transformation. Mutations were detectable in the chronic phase in 14 cases (67% of the total cohort and 74% of patients with mutations at transformation). Median number of mutations in the chronic phase was 1 (range: 1-3). The majority of mutations in the leukaemic phase were also detected in the chronic phase (67%, 100%, 80% and 100% for TET2, ASXL1, DNMT3A and SRSF2, respectively) whereas 43% and 25% of patients with mutations in TP53 and RUNX1 carried the same mutations in the chronic phase, usually at subclonal levels. In one case, the TP53 mutant load was 73%, but this sample corresponded to a late chronic phase that was collected just 1 year before leukaemic transformation.
Clinical and molecular characteristics according to the JAK2 V617F mutational status of the leukaemic clone
The original diagnosis of the 29 assessable cases was JAK2 V617F-mutated PV (n = 14), JAK2 V617F-mutated ET (n = 9), MPL-mutated ET (n = 1), and TN ET (n = 5). In 11 of the 23 (48%) JAK2-mutated patients who developed AML, the leukaemic evolution took place in a JAK2 V617F-negative clone. Overall, leukaemia was categorised as JAK2 V617F mutated or un-mutated in 12 (41%) and 17 (59%) patients, respectively. All patients had received cytoreduction with hydroxycarbamide before transformation. There were no significant differences among the two study groups in the proportion of patients receiving leukaemogenic agents.
In comparison with JAK2 V617F-unmutated patients, those with JAK2 V617F-mutated leukaemia showed significantly higher frequency of complex karyotypes (Table IV) . TP53 mutations were highly prevalent in JAK2 V617F-mutated leukaemia whereas only one JAK2 V617F-unmutated leukaemia was associated with TP53 mutations (P < 0Á0001, Table IV ). Mutations in RUNX1, EZH2 and DNMT3A genes were more prevalent in JAK2 V617F-unmutated leukaemia although the differences were not significant (Table SIII) . In two out of three patients with SRSF2 mutations there was an expansion of a RUNX1-mutated leukaemic clone (P = 0Á079 for the association), with four out of five RUNX1 mutations appearing in patients who had a JAK2 V617F-negative clone arising from a previous JAK2 V617F-positive MPN (Table SIII) . The JAK2 V617F mutational status of the leukaemic clone was significantly associated with survival (median survival 95 and 343 days for JAK2 V617F mutated and un-mutated, respectively, P = 0Á003, Figure S4 ).
Discussion
The results of the present study demonstrate the significant impact of the genotype on the risk of leukaemic transformation in patients with ET. Thus, patients with CALR-mutated ET had a much lower risk of transformation to acute leukaemia than the other molecular subtypes. Moreover, the incidence of AML in CALR-mutated ET was minimal, even after MF transformation. Limited evidence has previously been published on the protective effect of the CALR mutation regarding the risk of acute transformation in ET patients. In this respect, in a series of 717 ET patients, only two among the 176 CALR-mutated cases progressed to AML (Rumi et al, 2014b) . By contrast, 12 cases of AML transformation were seen among 466 JAK2 V617F-mutated patients, resulting in a cumulative incidence of AML of 2Á5% and 4Á3% for CALR and JAK2 V617F genotypes, respectively (Rumi et al, 2014b) . In our series, even more pronounced differences in AML risk were observed, with only one case of AML out of 117 CALRmutated ET patients as compared to 19 cases of AML/MDS out of 403 JAK2 V617F-mutated ET cases. Lundberg et al (2014) detected somatic mutations in additional non-driver genes in 18% of ET patients with the CALR genotype, a figure clearly lower than the 32% and 41% reported in JAK2 V617F-mutated ET and PV patients, respectively. In addition, CALR mutations are usually initial events whereas JAK2 V617F mutations may be initial or late events (Kralovics et al, 2006; Nangalia et al, 2013; Lundberg et al, 2014; Ortmann et al, 2015) . This difference in the frequency and timing of somatic mutations could explain the lower rate of AML/MDS transformation observed in patients with CALR genotype. In fact, in our cohort, 48% of AML cases evolving from patients with JAK2 V617F-mutated PV or ET appeared in a JAK2 V617F-negative clone, illustrating the important role of pre-JAK2 V617F somatic mutations in leukaemic transformation. To clarify this aspect it would be advisable to carry out NGS studies in our whole series of patients. Unfortunately, in the present study, available samples were restricted only to patients who progressed to AML/ MDS. Rampal et al (2014) , in a study performed mainly in patients with post-MF AML, showed that somatic TP53 mutations were common in JAK2 V617F-mutated post-MPN AML. In addition, in a murine model, expression of JAK2 V617F combined with loss of TP53 leads to fully penetrant AML (Rampal et al, 2014) . Similarly, Lundberg et al (2014) found the loss of heterozygosity in TP53 to be associated with AML transformation. In our study, restricted to patients with post-PV and post-ET AML, we observed a significant association between the acquisition of mutations in TP53 gene and the development of AML in a JAK2 V617F-mutated clone. Notably, these patients frequently showed a complex karyotype and a dismal outcome (median survival of 3 months only). In contrast, AML developing from a JAK2 V617F-negative clone displayed fewer cytogenetic abnormalities, a very low proportion of TP53 mutations and higher rate of mutations in RUNX, EZH2 and DNMT3A genes, suggesting that this type of leukaemia is mostly driven by a TP53-independent pathway. In addition, the survival probability of JAK2 V617F-negative leukaemia resembles that of elderly patients with de novo AML.
The analysis of paired samples by NGS showed that nondriver MPN mutations were already present in the chronic phase in most cases, with some important exceptions. Thus, while mutations in TET2, ASXL1, DNMT3A or SRSF2 genes were often detectable years before AML transformation, those in TP53 or RUNX1 genes were clearly associated with disease progression, as they were undetectable or present at subclonal levels in the early stages of MPN. Moreover, VAF confirmed the expansion of clones harbouring non-driver MPN mutations at time of acute transformation, supporting their contributory role in the pathogenesis of disease progression.
Our findings not only provide further insights into the mechanisms involved in MPN progression but, in addition, they might have potential implications for clinical practice. In general, the prognosis of post-MPN AML is poor (Tam et al, 2008; Kennedy et al, 2013) . Advanced patient age and the unfavourable results with standard intensive chemotherapy mean that most patients are usually offered palliative treatment only. However, our data suggest that the molecular profile of the leukaemic clone could be a useful useful guide for treatment decisions. Thus, patients with AML appearing in a JAK2 V617F-negative clone seem to have a more favourable disease profile and their treatment approach could be similar to that of de novo AML. On the other hand, patients with PV and ET in whom additional somatic mutations are detected at diagnosis or during follow-up could be candidates for molecular surveillance in order to document the expansion of clones with increased leukaemogenic potential. Another important clinical implication of molecular NGS assessment would be to avoid the exposure to leukaemogenic agents in those patients with non-driver MPN mutations in order to decrease the propensity to acute leukaemia.
In conclusion, our results indicate that CALR mutation is associated with a low risk of leukaemic transformation in ET patients. Non-MPN driver mutations play a key role in leukaemic transformation and can be detected by NGS techniques at MPN diagnosis in most cases. Finally, the JAK2 V617F mutational status of the leukaemic clone reflects different pathways of disease transformation that are associated with distinct clinical features and prognosis.
